Another phase Ib/IIa study (NCT03162224) examined the safety and efficacy of MEDI0457 in combination with anti-PD-L1 durvalumab for HPV+ R/M HNSCC. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.